Jeffrey Haskell, MD
Family Medicine · Arco, IDNPI 1073535506
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.5%), education and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Arthrex at 35.9% of the total. Reporting peaked in 2019 at $3,055 and has fallen 82.6% since, to $531 in 2025. Among family medicine clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $45.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$2K
- AbbVie$1K
- Active Medical, LLC$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$165
- Biohaven Pharmaceutical Holding Company Ltd.$65
- Vanda Pharmaceuticals Inc.$57
- plus $727 from 24 others
What the payments were for
- Travel & lodging$1,12921%
- Food & beverage$2,32943%
- Education$1,90235%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 4 | $1,927 |
| AbbVie(2 entities) | 64 | $1,291 |
| Active Medical, LLC | 2 | $1,129 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $165 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $65 |
| Vanda Pharmaceuticals Inc. | 3 | $57 |
| Axsome Therapeutics, Inc. | 4 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Novo Nordisk | 3 | $49 |
| Alkermes, Inc. | 2 | $48 |
| AstraZeneca(2 entities) | 3 | $48 |
| Xeris Pharmaceuticals, Inc. | 3 | $44 |
| Boston Scientific | 3 | $42 |
| Biohaven Pharmaceuticals, Inc. | 3 | $41 |
| Itamar Medical Inc | 1 | $36 |
| Jazz Pharmaceuticals Inc. | 1 | $34 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| Ferring Pharmaceuticals Inc. | 1 | $28 |
| Biodelivery Sciences International, Inc. | 2 | $26 |
| Therapeuticsmd, Inc. | 1 | $21 |
| Shield Therapeutics Inc | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Pfizer | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Harmony Biosciences LLC | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Viatris Specialty LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,360 in reported general payments places this provider in the 90th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 12 | $26,569 |
| VraylarCariprazine Hcl | 14 | $19,080 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,458 |
| Oxycodone Hcl | 85 | $3,743 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 66 | $1,821 |
| Gabapentin | 66 | $1,716 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 66 | $1,690 |
| Trazodone Hcl | 45 | $917 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 18 | $889 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 19 | $838 |
| Levothyroxine Sodium | 81 | $805 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 24 | $801 |
| Morphine Sulfate ErMorphine Sulfate | 21 | $590 |
| Testosterone Cypionate | 20 | $529 |
| Atorvastatin Calcium | 44 | $471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,291 | $19,08014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 803 family medicine providers in Idaho.
Other family medicine in Arco
- Kenneth CongerSandpoint$266K
- David ButukMeridian$206K
- Anne BroadwayIdaho Falls$184K
- Timothy McHughMeridian$165K
- Phyllis YouBoise$88K
- Ralph SutherlinSt Maries$73K
- Henry DownsCoeur D Alene$69K
- Crystal PyrakCoeur D Alene$46K
- Gary SoucieBlackfoot$37K
- Julian de Bruyn KopsIdaho Falls$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.